PHAP Medical, LLC

DISRUPTIVE BLOOD PUMP TECHNOLOGY
GENTLE PULSATILE FLOW

Motivation Text

OUR MOTIVATION

HEART DISEASE REMAINS THE LEADING CAUSE OF DEATH IN THE UNITED STATES

127.9 MILLION

PEOPLE DEVELOP HEART DISEASE EACH YEAR
IN THE U.S. ALONE

EVERY 33 SECONDS

ONE OF US WILL SUCCUMB TO A CARDIOVASCULAR EVENT

IN 2021
HEART DISEASE CLAIMED APPROXIMATELY

695,000 LIVES

IMAGINE THE ENTIRE POPULATION OF

WASHINGTON DC, BOSTON, LAS VEGAS OR PORTLAND

BEING TAKEN FROM US EACH YEAR

THESE ARE NOT JUST NUMBERS
THEY ARE LOVED ONES, OUR FAMILY AND FRIENDS

Our Mission
Our Mission

OUR MISSSION

CATHETER-DEPLOYED HEART ASSIST PUMPS

( Percutaneous Heart Assist Pump )

WE ARE DEVELOPING A SUITE OF ADVANCED MEDICAL DEVICES
ASSISTING PATIENTS EXPERIENCING ACUTE CARDIAC EVENTS

UNIQUE DESIGN OBJECTIVES

NO HIGH-SPEED SPINNING MOTOR OR IMPELLERS

DIRECTIONAL FLOW – REVERSE/BI-DIRECTIONAL/STANDARD

MINIMAL HARM TO RED BLOOD CELLS (HEMOLYSIS)

PULSATILE FLOW SIMILAR TO NATURAL HEARTBEAT

SUPERIOR BLOOD FLOW SUPPORTING EXTREMITIES

EXTENDED DURATION OF USE IN PATIENT

EXPANDED PATIENT ELIGIBILITY PROFILES

SMALL INSERTION SIZE

Recent Industry Acquisitions

RECENT INDUSTRY ACQUISITIONS

2015

$3.4 BILLION

ST JUDE MEDICAL ACQUIRES HEARTMATE

2016

$1.1 BILLION

MEDTRONIC ACQUIRES HEARTWARE

2017

$25 BILLION

ABBOTT ACQUIRES ST JUDE MEDICAL INCLUDING HEARTMATE

( HEARTMATE-II LVAD DEVICE )

APPROXIMATE YEARLY SALES

$1 BILLION

2022

$16 BILLION

JOHNSON & JOHNSON ACQUIRES ABIOMED

( THE MAKER OF THE IMPELLA DEVICE )

Recent Industry Growth

RECENT INDUSTRY GROWTH

STARTUP FUNDING

INDUSTRY LEADER EARLY-STAGE INTEREST

01-13-2022

FROM MEDICAL DESIGN & OUTSOURCING – MEDTRONIC CFO KAREN PARKHILL

“Most of what we do is early stage, we do some acquisitions that are already revenue-generating but much of what we do is indeed early stage where things are still in development or maybe finished development, but not yet commercialized. Then we can use our expertise and the Medtronic muscle to help get it through final regulatory approval, reimbursement, and then ultimately, take it commercially around the world.”

$59 MILLION

PROCYRION

(AORTIX PERCUTANEOUS HEART ASSIST IMPELLER PUMP

$40+MILLION

COREWARE

(LVAD PUMP WAVE TECHNOLOGY)

$15+MILLION

MAGENTA MEDICAL

(THE ELEVATE pLVAD)

$10+MILLION

SECOND HEART

(AORTIC STENT CIRCULATORY ASSIST PUMP )

Contact Information

FOR ADDITIONAL INFORMATION
PLEASE CONTACT

Phap Medical, LLC

3020 Red Hill, Ave
Costa Mesa, CA 92626
714-805-8455

CEO Babek Khamenian
BKhamenian@PhapMedicalllc.com